increment harder hit
edward post mix result thursday close top bottom-lin
beat overshadow miss global tavr adjust sale
report organ came street beat
entir driven stronger perform critic surgic heart
valv compani key transcathet valv busi fall short
grow well investor expect ep
came qualiti beat low
roughli driven tax save relat employe stock-bas comp
manag reiter upper-end sale growth guidanc continu
believ difficult edward hit upper-end thvt
growth rang consid global tavr growth market continu
slow edward lose share europ aggress competitor price
 growth impli mid-to-high teen growth exclud
cardioband appear aggress ep guidanc rais
portion beat quarter
factor due expect softer vs consensu
global transcathet valv sale came
flat result comp quarter significantli
easier vs repres faster expect deceler
growth seen growth alway expect
deceler go low-risk data next year underli growth
reiter guidanc upper-end rang reli
benefit upcom launch ultra centera continu access protocol
cap procedur trial cardioband mitral repair
estim us tavr sale quarter vs street
ou sale report
consensu us market edward procedur growth grew
mid-teen outsid us market procedur growth also mid-teen
edward grew underli compani lost share competitor
edward decid hold line price
accur valv abbott portico valv price discount
edward cost sensit market healthcar budget limit lower
price valv often win despit superior sapien clinic evid
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
forecast edward ww transcathet valv sale
bake us tavr sale ou
eu tavr sale japan sale final
thvt estim also includ contribut cardioband
look back balanc busi edward non-tavr segment drove
top-lin beat surgic heart valv sale beat
strong uptak recent launch inspiri resilia valv exclud
headwind compani shift consign inventori system
chang first made critic system sale
strong beat growth across portfolio led
continu adopt hemospher sale also benefit quarter
bottom-lin beat larg driven tax gross margin came
street expect fx headwind off-set profit
product mix hand sg came even includ
headwind consign convers came despit
continu invest clinic trial line tax vs
main driver beat factor benefit settl tax
audit told led cash ep quarter consensu
respect pipelin updat continu access protocol cap
trial track begin low risk data expect
march elsewher tavr european launch ultra track back
half year continu enrol supplementari clinic trial underway
relaunch centera also expect commenc time frame
follow minor modif deliveri system us pivot trial centera
patient single-arm studi one-year endpoint
also expect
commenc late third quarter move tmtt time-frame
harpoon launch remain uncertain compani continu look number
patient experienc complic last quarter enrol clasp ce
mark trial pascal remain track launch expect progress
continu made compani transsept program cardiaq
timelin provid tricuspid front compani track
begin earli feasibl studi cardioband tr us may limit
follow yesterday medcac panel ncd like final sometim
next month appear lack consensu medcac
panel yesterday healthi mix present support need volum
requir other stand firmli commentari made call today
larg in-lin yesterday press releas manag highlight lack
definit evid link high volum procedur high qualiti outcom
chang compani long-term think manag confid
reach opportun
conclud manag reiter revenu guidanc across board
rais ep less size beat balanc year
manag reiter revenu guidanc high end
rais ep guidanc bottom top
vs beat shortfal larg reflect
guidanc rang fall well street expect
revenu in-lin howev rang
captur street
move back half year establish decemb
price target valu share cash ep repres
signific premium current large-cap averag cash ep
believ warrant given edward differenti outlook top
invest thesi valuat risk
edward post solid start year still believ stock remain
stori revenu grow ep investor
like look forward releas edward medtron
risk tavr trial march compani transcathet mitral
tricuspid repair program begin ramp meaning contribut top-lin
perform first time therefor transit year albeit project
top-lin bottom-lin growth come risk howev
tavr market slow last sever quarter like slow
get risk trial fulli expect posit therefor
catalyst absent top-lin upsid meaning pipelin catalyst next
month think edward shape stori investor
want revisit later year remain neutral
dec price target valu share ep estim
repres signific premium current large-cap med-tech averag
ep believ premium justifi given edward differenti
outlook top bottom line
risk rate price
upsid risk rate includ better-than-expect tavr growth competitor
pipelin product failur better-than-expect critic perform
favor chang tavr procedur reimburs particularli intern
downsid risk rate includ increas competit us
clinic trial result setback compani transcathet mitral program
edward lifesci summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
